TILS.L Regulatory News (TILS)

11 Jun 2007 07:01

ReGen Therapeutics PLC11 June 2007 Data Showing that ReGen's Colostrinin(TM) Supports Healthy Cognitive FunctionPresented at the 2007 International Congress on Natural Medicine in Australia ReGen Therapeutics Plc (London, UK) is pleased to announce that a review ofscientific and clinical information on Colostrinin(TM), its nutraceuticalproduct which the Company believes has the potential to support healthycognitive function, was presented today at the 2007 International Congress onNatural Medicine in Surfers Paradise, Queensland, Australia by Dr Marian Kruzel,ReGen's Chief Scientific Officer. The conference, which is being attended by key opinion leaders and practitionersof natural medicine from around the world, is being sponsored by Metagenics Inc.of California via its Australian affiliate company Health World Ltd. Metagenics have licensed the rights to Colostrinin(TM) for the North Americanmarket and intend to introduce it in the USA as a nutritional supplement duringthe last quarter of 2007. Dr. Kruzel presented both pre-clinical and human clinical data showing thatColostrinin(TM): •reduces the production of intracellular reactive oxygen species (ROS). These increase with old age and are associated with tissue and metabolic damage •prevents the aggregation of beta-amyloid and its consequent neurotoxicity. This is a protein associated with Alzheimer's disease •increases the lifespan of mice prone to premature ageing by around 30% when given in the drinking water •is well-tolerated and without adverse effect when given to animals at doses up to 100 times that recommended for humans daily for prolonged periods •had beneficial effects on the cognitive and functional performance of around 150 human subjects in clinical trials with mild to moderate Alzheimer's disease. Commenting after his presentation Dr. Kruzel said, "The audience here isextraordinary, it includes physicians, health care professionals and many otherdisciplines concerned about wellbeing in rapidly aging societies. It is a greatpleasure to have the opportunity to present our cutting edge scientific researchthat validates the efficacy of nutraceutical strategies in the management ofneurodegenerative diseases to such an audience". Jeff Katke, Chairman and Chief Executive Officer of Metagenics added, 'Asadvocates of natural medicine we are very pleased to be close to introducingColostrinin(TM) in the US as we see it as an important part of our science-basedneurological product line and believe it will help to maintain the health of theageing population. Today's presentation by Dr Kruzel will be useful incommunicating the benefits of Colostrinin(TM) to a wider audience'. For further information, please contact: Andrew MarshallGreycoat CommunicationsTel: 020 7960 6007Mobile No: 07785 297111 Rod Venables/Cecil JordaanHB CorporateTel: 020 7510 8600 Percy LomaxReGen Therapeutics PlcTel: 020 7153 4920 This information is provided by RNS The company news service from the London Stock Exchange